1. Introduction {#s0005}
===============

Angiotensin-converting enzyme (ACE) has its homologue, ACE2 discovered in 2000 as a ACE related caroxypeptidase not inhibited by captopril \[[@bb0005],[@bb0010]\]. ACE2 was firstly shown to be expressed in the kidneys of both the normotensive and the spontaneously hypertensive rat strains \[[@bb0015]\]. Subsequent studies demonstrated down-regulation of renal ACE2 in three different models of hypertension \[[@bb0020]\]. Moreover, circulating and cardiac levels of angiotensin II (AT-II) were shown to increase in the ACE2-null mice. ACE2 is the principal pathway for Ang- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\] formation from AT-II (Ang-1-8), protecting against excessive activation of AT1 receptor in the heart tissues, However, newer findings suggested that ACE2 can be an important element in the renin--angiotensin aldosterone system \[[@bb0025]\]. Following these studies, ACE and ACE2 focused the attention of researchers for their contribution in diverse human disorders. Recently, the new coronavirus (2019-nCoV or SARS-CoV-2) outbreak which has affected people all over the world has further highlighted the role of ACE2. This virus has about 80% sequence identity with the severe acute respiratory syndrome (SARS)-related coronaviruses (SARS-CoVs) and 96% sequence identity to a bat coronavirus. Most remarkably, SARS-COV-2 was shown to utilize the similar cell entry receptor ACE2 as SARS-CoV \[[@bb0030],[@bb0035]\]. A recent study has shown that the ACE2-binding pocket for SARS-CoV-2 spike protein receptor-binding domain (RBD) is almost identical to this one of SARS-CoV RBD. Structural protein modeling led to identification of amino acid residues in SARS-CoV-2 RBD that critical in ACE2 binding. Notably, most of these residues are either highly conserved or have comparable side chain chemical properties with the SARS-CoV RBD. This similarity of the structure and amino acid sequence stimulated intensive debate on the convergent evolution of these viruses RBDs under a pressure of enhanced binding to ACE2 \[[@bb0040]\]. ACE2 has been shown to be expressed as a membrane bound protein in several human tissues such as lung, intestine, heart and kidney. The surface expression of this protein on was demonstrated on ciliated bronchial cells and on the lung alveolar epithelial cells but also in endothelial cells, which was stated a noticeable discovery \[[@bb0045]\]. Moreover, a recent in silico analysis of RNA-seq profiles verified expression of ACE2 in the mucosa of oral cavity \[[@bb0050]\].

[Fig. 1](#f0005){ref-type="fig"} shows the molecular mechanisms initiated after SARS-CoVs entry into the cells and the significance of ACE and ACE2 in these processes.Fig. 1The first step of conversion of angiotensinogen (AT) to AT-I is catalyzed by renin. Then, ACE converts AT-I to AT-II. Finally, ACE2 cleaves AT-II to produce AT- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\]. AT-II can bind with AT1R to initiate inflammation and fibrosis in lung tissue. However, binding of AT- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\] with MasR inhibits this process. SARS-CoVs exploits ACE2 for their entrance into the cells. A transmembrane serine protease TMPRSS2 has a crucial role in activation of the fusion of a virus with cell membrane. Moreover, the Furin protease which is proconvertase physiologically required to activate proteins in the Golgi apparatus mediates proteolysis of the spike protein S2 subunit, a unique feature for SARS-CoV-2 \[[@bb0055]\]. ACE2 levels are decreased in SARS-CoV infected cells leading to increase in AT-II and decrease in AT- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\] levels. Based on receptor effects of these proteins mediated by AT1R and MasR, these two alterations have synergic effects on induction of lung fibrosis. Moreover, AT-II has a role in degradation of ACE2 through ubiquitination \[[@bb0060]\]. SARS-CoVs also enhance expression levels of miR-200c-3p and miR-429 in the infected cells, both of them being regarded as ACE2 targeting miRNAs \[[@bb0065],[@bb0070]\] (ACE: angiotensin converting enzyme, ACEi: ACE inhibitor, AT: angiotensinogen, ARB: Angiotensin II receptor blocker).Fig. 1

In the current review, we discuss the expression pattern and function of the both ACE proteins in relation with the underlying disorders, administration of certain medications and the existence of common genomic variants within *ACE* genes to explain the differences in the response of affected individuals to SARS-COV-2.

2. Expression pattern of ACE and ACE2 in human disorders {#s0010}
========================================================

In agreement with the role of ACE2 on virus uptake by cells, up-regulation of human ACE2 has increased disease severity in mice infected with SARS-CoV \[[@bb0075]\]. Moreover, injecting SARS-CoV spike into mice has led to down-regulation of ACE2, thus aggravating the lung injury \[[@bb0080],[@bb0085]\]. Consequently, ACE2 functions as the cellular receptor for SARS-CoV entrance but also confers a protective mechanism against lung injury \[[@bb0090]\]. Based on these investigations, level of expression of ACE2 is an important factor in the SARS-CoV infection. Thus, comorbid conditions that influence expression of this protein might affect severity of disease. [Table 1](#t0005){ref-type="table"} summarizes the available data on abnormal expression of ACE and ACE2 in human/ animal disorders.Table 1Expression pattern of ACE and ACE2 in human disorders (↑: up-regulation, ↓: down-regulation).Table 1DiseaseExpression/ActivityClinical samplesFunctionReferenceACEACE2SARS-CoV infection--↑Human airway epithelial cells and lungSARS-CoV preferentially infects well-differentiated ciliated epithelial cells expressing ACE2\[[@bb0095]\]--↑Human (hu) 293 T kidney cellsEnhanced SARS-CoV S-mediated entry into 293 T cells transiently over-expressing ACE2\[[@bb0100]\]Diabetes↑↑STZ induced diabetic ratp38 MAPK, ERK and JNK hyperphosphorylation with unchanged expression\
\[[@bb0105]\]↑↓High glucose NRK-52E cells↓↓Diabetic Sprague-Dawley rat\'s kidney--\[[@bb0110]\]↑↓Kidney tissue from 20 patients with type 2 diabetesHigh ACE/ACE2 ratio in type 2 diabetes and overt nephropathy, contributed to renal injury\[[@bb0115]\]Hypertension↑↓SHR ratsActivated ACE/Ang II/AT1 arm and compromised ACE2/Ang \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\]/MasR arm in hypertensive brain\[[@bb0120]\]↑↓Hypertensive human kidney/heartAng II regulates ACE/ACE2 mediated by the AT1-ERK/p38 pathway in mRNA and protein levels\
\[[@bb0125]\]--↓Hypertensive rat kidney SHR and WKY ratsACE2 maps to a QTL associated with hypertension in three rat models of high blood pressure\[[@bb0020]\]--↑Male Sprague-Dawley ratsACE2 overexpression decreased AT1R and ACE expression and increased AT2R and Mas expression, attenuated proinflammatory cytokines TNF-α, IL-1β and IL-6 in the PVN.\[[@bb0130]\]Kidney disease↑↓STNx rat kidneyIncreased cortical ACE activity and reduced ACE2 activity in the medulla and cortex, increased plasma and urinary ACE2 activity\[[@bb0135]\]↑↑78 renal cortical specimensCorrelation between ACE and ACE2 gene expressions mediated via the local Ang II concentration\[[@bb0140]\]Cardiovascular--↑79 obstructive CAD PatientsElevated ACE2 activity, an independent predictor of CV mortality and MACE\[[@bb0145]\]--↑Heart and the kidney of GHR−/− miceExacerbation of the ACE2/Ang- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\]/Mas receptor axis\
\[[@bb0150]\]↑↑Myocardial infarction ratElevated expression of both ACE/ACE2 in border/infarct zone and MI-viable myocardium\[[@bb0155]\]--↑Human heart failure, IDC and ICMACE2 is upregulated in human IDC and ICM\[[@bb0160]\]Acute respiratory distress syndrome\
(ARDS)↓BALF and lung tissue of LPS-induced ARDS ratAEC2 attenuates LPS-induced ARDS via the Ang- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\]/Mas pathway by inhibiting ERK/NF-κB activation.\[[@bb0165]\]----31 ARDS patients (51% survivors)Higher ACE/ACE2 activities in survivors\[[@bb0170]\]Acute lung injury\
(ALI)↓LPS-induced ALI ratsThe expressions of VDR mRNA and ACE2 mRNA in LPS group was significantly lower than those in normal control group\[[@bb0175]\]↑↓LPS-induced ALI rats/ PMVECSUp-regulated ACE/Ang II/AT1R axis\[[@bb0180]\]--↓ACE2 knockout ALI-induced miceLoss of ACE2 expression resulted in severe ALI phenotypes and rhuACE2 can protect mice from severe acute lung injury\[[@bb0080]\]Neonatal lung injury--↓Alveolar epithelial A549 cellsProteolytic enzymes in meconium effectively degraded ACE-2 in human A549 cells and decreases its protective activity\[[@bb0185]\]Smoking--↑Human lung tissueSmokers may be more susceptible to 2019-nCov\[[@bb0190]\]Inflammatory bowel disease (IBD)--↑CD, UC patients with IBDACE2 activity and Ang \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\] concentrations and the ACE/ACE2 ratio were higher in patients with IBD\[[@bb0195]\]

Streptozotocin (STZ), immunohistochemical staining (IS), Western blot (WB), growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis, Growth hormone receptor knockout (GHR−/−) mice, major adverse cardiovascular events (MACE), Cardiovascular disease (CV), Idiopathic dilated cardiomyopathy (IDC), ischemic cardiomyopathy (ICM), Pulmonary microvascular endothelial cells (PMVECS), Recombinant human ACE2 protein (rhuACE2), Crohn\'s disease (CD) and ulcerative colitis (UC).

It is worth mentioning that adult stem cells which have immunomodulatory and pro-reparative activities in the local environment \[[@bb0200]\] might affect the process of SARS infection and tissue regeneration. The regenerative capacity of these cells \[[@bb0205]\] can be exploited for avoidance of tissue damage following infection. Yet, clinical evidence in this regard is scarce. Several medications have been shown to alter expression levels of ACE or ACE2. Administration of these medications not only can modify a risk of infection with SARS-CoV, but also can affect the disease course. [Table 2](#t0010){ref-type="table"} summarizes the results of studies which reported alteration of ACE or ACE2 levels following administration of certain medications.Table 2The effect of different treatments on the expression pattern of ACE and ACE2 (↑: up-regulation, ↓: down-regulation).Table 2TreatmentAffected proteinTreated DiseaseSamplesFunctionReferenceACEACE2Calcitriol--↑Acute lung injury (ALI)LPS-induced ALI ratsCalcitriol can increase the expressions of VDR mRNA and ACE2 mRNA and protein levels of VDR and ACE2.\[[@bb0175]\]--↑Hypertensive brainSHR and WKY rats/BV2 cellsDecreased Ang II, unchanged ACE and increased ACE2 suggested enhanced ACE2/Ang \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\]/MasR axis in vivo and vitro\[[@bb0120]\]↓↑Diabetic kidney diseaseSTZ induced diabetic rat /NRK-52E cellsRegulates ACE/ACE2 possibly by p38 MAPK or ERK, but not JNK pathways.\[[@bb0105]\]↓↑Acute lung injury (ALI)LPS-induced ALI rats/ PMVECSIinhibited ACE, AT1R, induced ACE2, suppressed renin and Ang II expression\[[@bb0180]\]↓↑HypertensionSHR and normotensive WKY ratsDownregulation of Ace in SHR rats and upregulation of Ace2 in normotensive WKY\[[@bb0210]\]ACEI--↑hepatic fibrosisLiver fibrosis/ hepatic stellate cells (HSC)ACE inhibitors can upregulate ACE2 under conditions of liver injury both in vivo and in vitro.\[[@bb0215]\]↓--myocardial infarction (MI)Viable myocardium of MI ratsACE inhibition was associated with inhibited cardiac ACE but ACE2 catalytic activity was unchanged.\[[@bb0155]\]--↑Acute kidney injury (AKI)Renal cortex and medulla in STNx-induced AKIRamipril had no effect on ACE or ACE2 mRNA expression in either STNx or Control kidneys but increased both cortical and medullary ACE2 activity.\[[@bb0220]\]DIZE--↑Hyperoxic lung injury (HLI)BALF and lung of HLI miceInhibited NF-κB pathway, activated Nrf2/HO-1/NQO1 pathway and reduces severity of HLI\[[@bb0225]\]--↑acute kidney injuryKidney cortex of STNx ratIncreased cortical ACE2 gene expression, increased ACE2 cortex and medulla activity. Reduced cortical ACE activity.\[[@bb0135]\]--↑myocardial infarction (MI)AMI ratSuppressed TNFα, IL-6, reduced COX-2 and iNOS, and activated ACE2/AT1R/MasR pathway.\[[@bb0230]\]↓↑diabetic nephropathy (DN)Kidney of DN ratRestored ACE2 levels and further increased of AT2 receptors expression\[[@bb0235]\]Statin--↑DiabetesSTZ induced diabetic ratCombined fluvastatin/insulin treatment more efficiently prevents diabetic cardiomyopathy.\[[@bb0240]\]--↑thickening after vascular balloon injuryWistar ratsUpregulation of ACE2, an increase in Ang- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\], downregulation of AT1, and activation of the P-ERK pathway.\[[@bb0245]\]↓↑diabetic myocardiumSTZ induced diabetic ratAttenuated ACE/ACE2 ratio to normal values\[[@bb0250]\]Fasudil↓↑Acute pulmonary embolism (APE)SD rat PAECsACE2 activation by ROCK inhibitor for APE treatment\[[@bb0255]\]↓↑Myocardial fibrosisOverload pressure model of SD ratsFasudil inhibits overload pressure-induced myocardial fibrosis by improving ACE2 and angiotensin \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\].\[[@bb0260]\]↓↑HypertensionHypertensive DOCA)-salt ratIncreased vascular and plasma ACE2 activity, reduced Ang II and increased Ang- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045]\] plasma levels.\[[@bb0265]\]--↑Hypoxic pulmonary hypertension (HPH)Hypoxia-Induced PH rats/PASMCUp-regulated Ang- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\] and ACE2, and lessened HIF-1α attenuate the PVSR and PH.\[[@bb0270]\]

Acute Lung Injury (ALI), AXCE inhibitor (ACEI), Lipopolysaccharide (LPS), Brain of spontaneously hypertensive rats (SHR), Wistar--Kyoto (WKY), microglial cells (BV2), Streptozotocin (STZ), Rat renal tubular epithelial cells (NRK-52E), Pulmonary microvascular endothelial cells (PMVECS), Hearts of spontaneously hypertensive rats (SHR), Renal tubular epithelial cells cultured in high-glucose medium (MTC), ACE2 agonist diminazene aceturate (DIZE), Bronchoalveolar lavage fluid (BALF), Subtotal nephrectomy (STNx), Acute myocardial infarction (AMI), Sprague-Dawley rats (SD), Fasudil: Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor, Deoxycorticosterone acetate (DOCA)-salt hypertensive rat, pulmonary vascular structure remodeling (PVSR).

3. Association between ACE/ACE2 polymorphisms and human disorders {#s0015}
=================================================================

Several potentially functional gene polymorphisms have been identified in ACE and ACE2. Associations between these polymorphisms and human disorders have been assessed in different populations. The ACE gene I/D polymorphism, 287-bp sequence insertion or deletion of DNA in intron 16 (rs4340, rs4646994), is perhaps the most studied polymorphism in this regard. Being associated with the onset and course of diabetic nephropathy \[[@bb0275],[@bb0280]\], the I/D genotype is regarded as a determinant of ACE expression levels in plasma, cells, and tissues \[[@bb0285], [@bb0290], [@bb0295]\]. Moreover, the ACE2 rs2074192 and rs2106809 polymorphisms have been associated with lower levels of circulating AT- \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\] \[[@bb0300]\]. [Table 3](#t0015){ref-type="table"} shows the results studies which assessed the association between ACE polymorphisms and human disorders.Table 3Association between ACE/ ACE2 polymorphisms and human disorders in different populations.Table 3GeneSNPDiseaseTreatmentCase/ControlPopulationConclusionReferenceACEACE I/DKidney Disease and HypertensionACE inhibitor ramipril347African AmericanII or DD homozygous genotypes and homozygous ACE haplotypes confer faster response to Ramipril.\[[@bb0305]\]HypertensionACEI Enalapril, Lisinopril or Imidapril190 (70 with cough /120 without cough)JapaneseACE-inhibitor-induced cough was not related to the ACE polymorphism.\[[@bb0310]\]ACEI-induced coughACE inhibitor144/105SpanishThe rs4646994 I allele is associated with cough (protective effect in males and risk conferring in females).\[[@bb0315]\]Erectile dysfunctionSildenafil113/118GermanACE II homozygous patients are better responder to sildenafil.\[[@bb0320]\]hypertrophic cardiomyopathy (HCM)--368 MYPBC3 mutation carriersDutchACE-DD was significantly associated with the Wigle score.\[[@bb0325]\]Post exercise CK increase--70 Healthy athletesAshkenazi and non-Ashkenazi CaucasianACE II/ID was associated with elevated CK activity and higher peak CK levels.\[[@bb0330]\]Psoriasis--207/ 182Austrian CaucasianACE II genotype was associated with higher risk of early-onset psoriasis.\[[@bb0335]\]cardiometabolic diseaseChlorthalidone, calcium channel blocker (amlodipine) or ACEi (lisinopril)9309/ 8164--ACE I/D polymorphism was associated with fasting glucose level during antihypertensive treatment.\[[@bb0340]\]Heart failure (HF)--58Canadian CaucasianAGT (T235)/ACE(D) combined polymorphisms associated with HF predisposition\[[@bb0345]\]Pneumonia--1239/2400Asian\
CaucasianACE-DD genotype of rs4340 polymorphism is associated with increased risk of pneumonia\[[@bb0350]\]Multiple sclerosis (MS)IFN-β1a treatment391/ 380PersianHigher prevalence of ACE I allele in MS patients, overrepresentation of the I allele in irresponsive patients to IFN-β.\[[@bb0355]\]Healthy persons--80CaucasiansACE I allele is associated with higher serum level of ACE.\[[@bb0360]\]ACE 2rs1978124 (A1075G)HypertensionAnti-hypertensive (F/M %) 16.05/ 12.591009/756Chinese HanSignificant haplotype:\
G-T-G-G-A (rs1978124, rs2106809, rs1403543, rs5194, rs56204867)\[[@bb0365]\]Retinopathy T2DM--743 cases DR/DNR\
F: 237/171\
M:182/153Chinesers2074192 (TT) and rs714205 (CC) were higher in DR in female (*P* \< .05).\[[@bb0370]\]rs879922T2 Diabetes--275/272UygursThe rs1978124, rs2048683, rs2074192, rs233575, rs4240157, rs4646156, rs4646188 and rs879922 were associated with T2D. The rs879922 is common maker for T2D and related cardiovascular risks.\[[@bb0375]\]rs2106809hypertrophic cardiomyopathy--261/ 609Chinese HanT allele of rs2106809 and C allele of rs6632677 conferred risk for HCM.\[[@bb0380]\]HypertensionACEI Benazepril/\
Imidapril497 hypertensive patientsChinese HanLower BP in CC/CT carrier female\[[@bb0385]\]--246/274Odisha, IndiaACE (DD) and rs2106809 (TT) were associated with disease in females.\[[@bb0390]\]Atenolol, Hydrochlorothiazide, Captopril, or Nifedipine3408 untreated hypertensive patientsChinese HanT allele confers a high risk for hypertension and reduced antihypertensive response to ACE inhibitors.\[[@bb0395]\]AF--265/289Chinese Hanrs2106809 (T) conferred higher risk of AF in males.\[[@bb0400]\]rs2074192Hypertension--647 cases\
289 LVH/ 358Chinese HanACE2 tag SNPs rs2074192 and rs2106809 as well as major haplotypes CCGC and TCGT are associated with blood pressure and LVH.\[[@bb0405]\]rs4646176Blood pressureHigh/low-sodium intervention1906 cases from 637 familiesChinese Hanrs1514283, rs1514282, and rs4646176 were significantly associated with SBP, DBP, or MAP responses to low and high-sodium intervention.\[[@bb0410]\]rs2285666 (G8790A)fatal CAD events--1382 CAD/ 453 fatal CADFinnish, Swedish, Irish, Frenchrs2285666 (A) significantly associated with the risk of cardiovascular death in female.\[[@bb0415]\]hypertension\
T2 Diabetes with stroke--7251 casesHan ChineseG8790A is a risk factor for hypertension in Han-Chinese males, and females from other ethnicities.\[[@bb0420]\]

Wigle\'s score, a point score system which takes into account the thickness of the ventricular septum, hypertrophic cardiomyopathy (HCM), Blood pressure (BP), Type 2 diabetes mellitus (T2DM), diabetes with retinopathy (DR), without retinopathy (DNR), Hypertrophic cardiomyopathy (HCM), Lone atrial fibrillation (AF), Hypertensive left ventricular hypertrophy (LVH), Systolic/diastolic blood pressure (SBP/DBP).

4. Associations between microRNAs (miRNAs) and ACE-related pathways {#s0020}
===================================================================

MicoRNA (miRNAs) as regulators of gene expression have been involved in several ACE-related pathways and have been shown to alter expression of ACE proteins or being altered by ACE proteins. These small-sized RNAs can bind with the 3′ untranslated region (3′ UTR) of their targets to stimulate degradation of the target mRNA and suppress translation. Moreover, miRNAs can interact with 5′ UTR, coding regions, and promoters, thus regulating gene expression by various mechanisms. Secretion of miRNAs in extracellular components provides them the ability to participate in the cell-cell communication \[[@bb0425]\]. [Table 4](#t0020){ref-type="table"} shows the results of studies which assessed association between miRNAs and ACE proteins.Table 4Summary of studies which assessed association between miRNAs and ACE proteins.Table 4miRNADiseaseSamplesFunctionReferencelet-7bHypoxic pulmonary hypertension (HPH)let-7b−/− ratHIF-1α-dependent hypoxia stimulated let-7b inhibited ACE2 expression via the HIF-1α-let-7b-ACE2 axis and contributed to the HPH\[[@bb0430]\]miR-421Cardiovascular disease (CVD)Primary cardiac myofibroblastsmiR-421 down-regulates ACE2 expression.\[[@bb0070]\]Chronic Kidney Disease (CKD)Circulating leukocytesA significant, inverse correlation between circulating miR-421serum level and the ACE2 expression in leucocytic was shown. Also, ACE2 upregulation following Anti-miR-421 treatment was reported\[[@bb0435]\]miR-1246acute lung injury (ALI)LPS-exposed pulmonary microvascular endothelial cells (PMVECs)miR-1246 meditates LPS-induced pulmonary endothelial cell apoptosis in vitro and ALI in mouse models, by targeting ACE2.\[[@bb0440]\]miR-200c-3pAcute respiratory distress syndrome (ARDS)HEK293T cellsAvian influenza virus H5N1 induced the miR-200c-3p upregulation via an NF-κB dependent manner to reduce ACE2 levels and cause lung injury\[[@bb0065]\]miR-483-3pVascular diseaseshuman embryonic kidney (HEK-293)miR-483-3p target 3′-UTRs of AGT, ACE-1, ACE-2 and AT2R\[[@bb0445]\]miR-4262acute lung injury (ALI)bleomycin-induced ALI mouseACE2-induced suppression of miR-4262, which lead to Bcl-2 protein upregulation, decreased the ALI severity by inhibiting the apoptosis of PECs\[[@bb0450]\]

Hypoxic pulmonary hypertension (HPH), let-7b knockout (let-7b−/−), Doxorubicin-induced heart cardiomyopathy (DHC), ALI-induced apoptosis of pulmonary endothelial cells (PECs).

5. Discussion {#s0025}
=============

In the current study, we reviewed the available literature about the expression pattern of ACE peptidases and the influence of various disorders and medications on the levels of these proteins. Expression level of ACE2 has importance in severity of infection with SARS-COV-2 and the extent of lung injury \[[@bb0090]\]. Most recently, human recombinant soluble ACE2 (hrsACE2) has been shown to inhibit growth of SARS-CoV-2 and interrupt early stages of infections with this virus \[[@bb0455]\].

Based on the abundance of genetic modifying factors in determination of ACE2 levels, it is advisable to create a risk predictive panel to determine propensity for severe infection of individual. Whole genome sequencing of the patients\' samples is the best method for identification of genetic variants that determine severity of the disorder. If a few genes were recognized that have a significant impact on the variability of COVID-19 course, a genetic test for coronavirus susceptibility could be simple to make, cheap and accurate. However, much more genes could be involved in this process. Perhaps a complex regulatory pattern of genetic expression which is involved in the physiology of the lung and upper respiratory tract shape in addition to ACE2 might contribute in this disorder.

Assessment of association between ACE proteins expression and human disorders has implications in health consequences after recovery from the primary SARS-CoV-2 infection. This would be a next important issue after extinguishing of the pandemia.

Hypertension is reported to be the most common comorbidity in SARS-CoV-2 infection \[[@bb0460]\], and the ACE protein is a target for ACE-inhibitors which are used in the treatment of hypertension to ultimately decrease the amount of Ang II. Some polymorphisms in ACE gene are reported to influence the efficacy of these inhibitors among them is the homozygous ACE haplotypes which lead to faster response to ramipril \[[@bb0305]\]. The expression and function of the ACE itself are affected by its polymorphisms which are associated with susceptibility to different diseases such as hypertension and diabetes mellitus \[[@bb0465]\]. Notably, polymorphisms in both ACE and ACE2 are important in the regulation of the ACE2 expression \[[@bb0470],[@bb0475]\].

On the other hand, a meta-analysis has reported association between the administration of ACE inhibitors and reduction in risk of pneumonia. Notably, ACE inhibitors may be more efficient in reducing the risk of pneumonia in Asian patients. Also, treatment with ACE inhibitors was associated with a significant reduction in risk of pneumonia-related mortality compared with controls \[[@bb0480]\]. This may be also related to the dual effect of ACE2 in viral infection and protection against acute respiratory distress syndrome.

Although the ACE/ACE2 regulation is complicated, it seems that in the absence of ACE the accumulation of angiotensin I may lead to the upregulation of ACE2. Whether this could facilitate the viral infection, is plausible because ACE2 is considered as a specific target for coronavirus treatment \[[@bb0475]\]. It means that the population-based differences in the ACE2 expression may affect the efficacy of a future antiviral treatment.

In brief, we summarize that coronaviruses, such as SARS-CoV and SARS-CoV-2, utilize ACE2 receptor for cell entry and infection. We know that the most severe consequence of the SARS-CoV-2 is pneumonia, which developes mostly in eldery males and subjects with comorbidities like diabetes, kidney disease, hypertension \[[@bb0485]\]. Besides, ACE2 has a protective role against acute respiratory distress syndrome. Thus, it can be concluded that decreased ACE2 level contributes to severe consequences of SARS-CoV-2 infection, while ACE2 is essential for the virus-cell fusion. One explanation for this controversy is a viral-induced transitional overexpression of ACE2 at the first stage of the infection \[[@bb0490]\]. However, a recent in silico analysis of sex bias severity of SARS-CoV-2 infection did not support the association between ACE2 genetic variants and disease severity/sex bias in the Italian population. Yet, TMPRSS2 levels and genetic variants were suggested as potential candidate modulators of the disease course \[[@bb0495]\].

Accordingly, among the top 38 eQTLs in ACE2, the strongest expression positive eQTL is more prevalent in East Asian females \[[@bb0500]\]. We also suggest epigenetic regulation by the potential miRNAs targeting on ACE2 transcripts. The results of the Targetscan database ([www.targetscan.org](http://www.targetscan.org){#ir0005}) list miR-200c-3p and miR-429 among the most prominent miRNAs that target ACE2. Up-regulation of miR-200c-3p is induced by a viral infection which leads to the downregulation of ACE2 \[[@bb0065]\]. Also, miR-421 is proved to downregulate ACE2 translation \[[@bb0070]\].

Interestingly, we have analyzed the well-studied I/D in *ACE* in Iranian patients with multiple sclerosis and reported association between this polymorphism and response to Interferon-β treatment \[[@bb0355]\]. Thus, ACE/ ACE2 polymorphisms not only can predispose individuals to diverse diseases, but also they can modulate response of patients to therapeutic options. Both activities have implications on the susceptibility to SARS-CoV-2 infection and the disease course. Another research era might be the identification of the difference between ACE/ACE2 expression levels and their regulating factors, such as the mentioned eQTL and miRNAs, between patients with severe and mild symptoms in different ethnic groups to find the possible effect of ethnicity, gender and the period of the disease on the ACE/ACE2 expression.

In addition to the routine models for investigation of the pathological events during infections, tissue engineering methods particularly "advanced biomaterials" or "functionalized scaffolds" \[[@bb0505]\] would provide study models to investigate the potential of such approaches in the treatment of the disorder. As an advance in the field of functional studies, the obtained results from "safe" in-vitro models which work without any additive can be applied in human models \[[@bb0510]\].

Taken together, the data presented above show the diversity of factors that modulate ACE/ ACE2 expression both in physiological conditions and in the course of SARS-CoV-2 infection. Different levels of expression and function of the ACE proteins, underlying disorders such as diabetes and hypertension, administration of certain medications, especially ACE inhibitors and calcitriol, and the existence of certain genomic variants within *ACE* genes that modulate function or expression of the encoded proteins are possible explanations for the observed difference in the response of individuals to the SARS-CoV-2 infection. Exploration of the role of these factors can lead to design of appropriate therapeutic modalities based on the personalized risks. Such personalized approach is expected to be more effective. Exploitation of the next generation sequencing methods at both genomic and transcriptomic levels would be a practical strategy in this regard.

In conclusion, the observed differences in the course of SARS-CoV-2 infection can be attributed to several genetic factors, comorbidities and administration of medical regimens that modulate expression of ACE proteins.
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